

MAY-11-2007 FRI 01:41 PM

FAX NO.

RECEIVED
CENTRAL FAX CENTER

P. 01

MAY 11 2007

P.O. Box 747
Falls Church, Virginia 22040-0747
Phone: (703) 205-8000
Fax: (703) 205-8050
(703) 698-8590 (GTV)

Birch, Stewart, Kolasch & Birch, LLP

Fax

To:	USPTO	From:	BSKB
Fax:	(571) 273-8300	Pages:	11 (including cover sheet)
Application No(s):	10/534,257	Our Ref(s):	1110-0326PUS1
Subject:	Request for a Corrected Official Filing Receipt		

This transmission is intended for the sole use of the individual and entity to whom it is addressed, and may contain information that is privileged, confidential, and exempt from disclosure under applicable law. You are hereby notified that any dissemination, distribution, or duplication of this transmission by someone other than the intended addressee or its designated agent is strictly prohibited. If your receipt of this transmission is in error, please notify this firm immediately by collect call to (703) 205-8000, and send the original transmission to us by return mail at the address above.


CERTIFICATE OF TRANSMISSION UNDER 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted to the United

States Patent and Trademark Office

MAY 11 2007

on _____


Signature

Yvette Punch
Printed name of person signing Certificate

Note: Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper.

MAY-11-2007 FRI 01:42 PM

FAX NO.

P. 02

RECEIVED
CENTRAL FAX CENTER

MAY 11 2007

PATENT
1110-0326PUS1

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant(s): FURUSAKO, Shoji et al. Conf.: 4508
Appl. No.: 10/534,257 Group: Unknown
Filed: May 10, 2005 Examiner: Unknown
For: ASSAY KIT AND ANTIBODY FOR HUMAN LOW
MOLECULAR WEIGHT CD14

REQUEST FOR A CORRECTED OFFICIAL FILING RECEIPT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

MAY 11 2007

Sir:

Attached hereto is the Official Filing Receipt in connection
with the above-identified application.

THE FOLLOWING CORRECTION(S) IS/ARE RESPECTFULLY REQUESTED:

DOMESTIC PRIORITY DATA AS CLAIMED BY APPLICANT

Change From: "PCT/JP03/14369"

TO: --PCT/JP03/14389--

It is respectfully requested that the U.S. Patent and
Trademark Office forward/issue a new Filing Receipt with the
correction(s) indicated above. Support for the correction(s) is
readily apparent on the enclosed photocopy of the Declaration and
Power of Attorney and forms PCT/IB/304 and PCT/IB/308 documents.

If necessary, the Commissioner is hereby authorized in this,
concurrent, and future replies, to charge payment or credit any

Appl. No. 10/534,257

overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By MaryAnne Armstrong, #40,069

P.O. Box 747
Falls Church, VA 22040-0747
(703) 205-8000

MAA/yp
1110-0326PUS1

Attachment(s)

COPY

RECEIVED
CENTRAL FAX CENTER

MAY 11 2007



UNITED STATES PATENT AND TRADEMARK OFFICE


UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPL NO.	FILING OR 371(C) DATE	ART UNIT	PIL FEE REC'D	ATTY. DOCKET NO	TOT CLMS	IND CLMS
10/534,257	05/10/2005	1645	2250	1110-0326PUS1	22	8

CONFIRMATION NO. 4508

2292
BIRCH STEWART KOLASCH & BIRCH
PO BOX 747
FALLS CHURCH, VA 22040-0747

FILING RECEIPT




OC00000022286324

Date Mailed: 03/20/2007

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Shoji Furusako, Shizoka, JAPAN;
Kamon Shirekawa, Shizuoka, JAPAN;Power of Attorney: The patent practitioners associated with Customer Number 02292.

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/JP03/14369 11/12/2003

Foreign Applications

JAPAN 2002-328866 11/12/2002
JAPAN 2003-330775 09/22/2003

If Required, Foreign Filing License Granted: 01/31/2007

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US10/534,257**

Projected Publication Date: 05/10/2007

Non-Publication Request: No

Early Publication Request: No

COPY

RECEIVED
CENTRAL FAX CENTER

MAY 11 2007

Title

Assay kit and antibody for human low molecular weight cd14

Preliminary Class

530

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process simplifies the filing of patent applications on the same invention in member countries, but **does not** result in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at <http://www.uspto.gov/web/offices/pac/doc/general/index.html>.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, <http://www.stopfakes.gov>. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

COPY

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

COPY

ATTORNEY DOCKET NO. 1110-0326PUS1

PTO/SB-100 (3-00)

Approved for use through 10/31/02. OMIB 0631-0022
Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it displays a valid OMB control number.

Declaration and Power of Attorney for Patent Application

特許出願宣言書及び委任状

Japanese Language Declaration

日本語宣言書

私は、以下に記名された発明者として、ここに下記の通り宣言する：

As a below named inventor, I hereby declare that

私の住居、郵便の宛先として国等は、私の氏名の後に記載された通りである。

My residence, post office address and citizenship are as stated next to my name.

下記の名前の発明について、特許請求範囲に記載され、且つ特許が求められている発明主題に関して、私は、最初、最先且つ唯一の発明者である（唯一の氏名が記載されている場合）か、或いは最初、最先且つ共同発明者である（複数の氏名が記載されている場合）と信じている。

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

ASSAY KIT AND ANTIBODY FOR HUMANLOW MOLECULAR WEIGHT CD14

上記発明の明細書はここに添付されているが、下記の欄がチェックされている場合は、この限りでない：

the specification of which is attached hereto unless the following box is checked:

☒ November 12, 2003 の日に出版され、
この出願の米国出願番号またはPCT国際出願番号は、
PCT/JP03/14389 であり、且つ
の日に補正された出版（適用する場合）☒ was filed on November 12, 2003
as United States Application Number or
PCT International Application Number
PCT/JP03/14389 and was amended on
(if applicable).

私は、上記の補正書によって修正された、特許請求範囲を含む上記明細書を検討し、且つ内容を理解していることをここに表明する。

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

私は、連邦規則法典第37編規則1.56に定められている、特許法について重要な開示を指示する義務があることを認める。

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

Duration Hour Statement: This form is estimated to take 0.4 hours to complete. Time will vary depending upon the need of the individual case. Any comments as the amount of time you are required to complete this form should be sent to Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents and Trademarks, Washington, DC 20231.

Page 1 of 3

ATTORNEY DOCKET NO. 111140-326PUS1

PTO/SI/106 (5-00)

Approved for use through 10/1/02. OMB 0651-0032
Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1997, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Japanese Language Declaration
(日本語宣言書)

私は、ここに、以下に記載した外国での特許出願または発明者等の出願、或いは米国以外の少なくとも一国を指定している米国法典第35編第385条(a)によるPCT国際出願について、同第110条(a)(4)項又は第385条(b)項に基づいて優先権を主張するとともに、優先権を主張する本出願の出願日より前の出願日を有する外国での特許出願または発明者等の出願、或いはPCT国際出願については、いかなる出願も、下記の枠内をチェックすることにより示した。

I hereby claim foreign priority under Title 35, United States Code, Section 110(a)(4) or 385(b) of any foreign application(s) for patent or inventor's certificate, or 385(a) of any PCT international application which designated at least one country other than the United States listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT international application having a filing date before that of the application for which priority is claimed.

Prior Foreign Application(s)

外国での先行出願

(Number) (番号)	(Country) (国名)	(Day/Month/Year Filed) (出願日/月/年)
2002-328866	Japan	12 / November / 2002
2003-330775	Japan	22 / September / 2003

Priority Not Claimed

優先権主張なし

私は、ここに、下記のいかなる米国仮特許出願についても、その米国法典第35編第110条(a)項の利益を主張する。

I hereby claim the benefit under Title 35, United States Code, Section 110(a) of any United States provisional application(s) listed below.

(Application No.) (出願番号)	(Filing Date) (出願日)	(Application No.) (出願番号)	(Filing Date) (出願日)
-----------------------------	------------------------	-----------------------------	------------------------

私は、ここに、下記のいかなる米国出願についても、その米国法典第35編第120条に基づく利益を主張し、又米国を指定するいかなるPCT国際出願についても、その同第385条(a)に基づく利益を主張する。また、本出願の発明者等の権利の主題が、米国法典第35編第112条第1段に規定された状態で、先行する米国出願又はPCT国際出願に開示されていない場合においては、その先行出願の出願日と本国内出願日又はPCT国際出願日との間の期間中に入手された情報で、連邦規則法典第37編規則1.88に定められた特許法に關する重要な情報について開示義務があることを示唆する。

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s), or 385(c) of any PCT international application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of Title 35, United States Code Section 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.55 which became available between the filing date of the prior application and the national or PCT international filing date of application.

(Application No.) (出願番号)	(Filing Date) (出願日)	(Status: Patented, Pending, Abandoned) (状態: 特許許可、係属中、放棄)

私は、ここに表明された私自身の知識に依る陳述が真実であり、且つ指図と信ずることに基づく陳述が、真実であると信じられることと等しい。さらに、故意に虚偽の陳述などを行った場合は、米国法典第18編第1001条に基づき、罰金または刑罰、若しくはその両方により懲罰され、またそのような虚偽による虚偽の陳述は、本出願またはそれに対して発行されるいかなる特許も、その有効性に問題が生ずるときを察知した上で陳述が行われたことを、ここに宣言する。

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

ATTORNEY DOCKET NO. 1110-0326PUS1

PTO/SD/116 (5-00)
 Approved for use through 10/3/02. OMB 0631-0032
 Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Japanese Language Declaration (日本語宣言書)

責任者: 私は本出願を審査する手続を行い、且つ米特許庁長官との全ての関係を行うため、記名された発明者として、下記の発明者及び/または弁理士を任命する。(氏名及び登録番号を記載すること)

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and conduct all business in the Patent and Trademark Office connected therewith (full name and registration number).

The practitioners are BIRCH, STEWART, KOLASCH & BIRCH, LLP or CUSTOMER NO. 2292

書類送付先

Send Correspondence to:

BIRCH, STEWART, KOLASCH & BIRCH, LLP or CUSTOMER NO. 2292
 P.O. Box 747 • Falls Church, VA 22040-0747 • U.S.A.
 Telephone: 703-205-8000 • Facsimile: 703-205-8050

直接電話連絡先: (氏名及び登録番号)

Direct Telephone Calls to: (name and telephone number)

第一発明者(第一発明者氏名)	Full name of sole or first inventor
Shoji Furusako	Shoji FURUSAKO
発明者の署名	Inventor's signature
Shoji Furusako	Shoji Furusako
住所	Residence
Shizuoka, Japan	Shizuoka, Japan
国籍	Citizenship
Japanese	Japanese
郵便の宛先	Post Office Address
c/o Mochida Pharmaceutical Co., Ltd.	c/o Mochida Pharmaceutical Co., Ltd.
7, Yotsuya 1-chome, Shinjuku-ku, Tokyo 160-8515 Japan	7, Yotsuya 1-chome, Shinjuku-ku, Tokyo 160-8515 Japan
第二共同発明者がある場合、その氏名	Full name of second joint inventor, if any
Kamon Shirakawa	Kamon SHIRAKAWA
第二共同発明者の署名	Second inventor's signature
Kamon Shirakawa	Kamon Shirakawa
住所	Residence
Shizuoka, Japan	Shizuoka, Japan
国籍	Citizenship
Japanese	Japanese
郵便の宛先	Post Office Address
c/o Mochida Pharmaceutical Co., Ltd.	c/o Mochida Pharmaceutical Co., Ltd.
7, Yotsuya 1-chome, Shinjuku-ku, Tokyo 160-8515 Japan	7, Yotsuya 1-chome, Shinjuku-ku, Tokyo 160-8515 Japan
(第三以下の共同発明者についても同様に記載し、署名すること)	(Supply similar information and signature for third and subsequent joint inventors.)

COPY

PCT/JP2003/014389

PATENT COOPERATION TREATY

PCT

NOTIFICATION CONCERNING
SUBMISSION OR TRANSMITTAL
OF PRIORITY DOCUMENT

(PCT Administrative Instructions, Section 411)

From the INTERNATIONAL BUREAU

To:

WATANABE, Mochitoshi
Hayakawa-tonakai Bldg. 13th FLOOR PATENT
12-5, Iwamoto-cho 2-chome
Chiyoda-ku, Tokyo 101-0002
Japan

RECEIVED

Date of mailing (day/month/year) 13 January 2004 (13.01.2004)	IMPORTANT NOTIFICATION		
Applicant's or agent's file reference PCT222			
International application No. PCT/JP2003/014389	International filing date (day/month/year) 12 November 2003 (12.11.2003)		
International publication date (day/month/year) Not yet published	Priority date (day/month/year) 12 November 2002 (12.11.2002)		
Applicant MOCHIDA PHARMACEUTICAL CO., LTD. et al			

- By means of this Form, which replaces any previously issued notification concerning submission or transmittal of priority documents, the applicant is hereby notified of the date of receipt by the International Bureau of the priority document(s) relating to all earlier application(s) whose priority is claimed. Unless otherwise indicated by the letters "NR", in the right-hand column or by an asterisk appearing next to a date of receipt, the priority document concerned was submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b).
- (If applicable) The letters "NR" appearing in the right-hand column denote a priority document which, on the date of mailing of this Form, had not yet been received by the International Bureau under Rule 17.1(a) or (b). Where, under Rule 17.1(a), the priority document must be submitted by the applicant to the receiving Office or the International Bureau, but the applicant fails to submit the priority document within the applicable time limit under that Rule, the attention of the applicant is directed to Rule 17.1(c) which provides that no designated Office may disregard the priority claim concerned before giving the applicant an opportunity, upon entry into the national phase, to furnish the priority document within a time limit which is reasonable under the circumstances.
- (If applicable) An asterisk (*) appearing next to a date of receipt, in the right-hand column, denotes a priority document submitted or transmitted to the International Bureau but not in compliance with Rule 17.1(a) or (b) (the priority document was received after the time limit prescribed in Rule 17.1(a) or the request to prepare and transmit the priority document was submitted to the receiving Office after the applicable time limit under Rule 17.1(b)). Even though the priority document was not furnished in compliance with Rule 17.1(a) or (b), the International Bureau will nevertheless transmit a copy of the document to the designated Offices, for their consideration. In case such a copy is not accepted by the designated Office as priority document, Rule 17.1(c) provides that no designated Office may disregard the priority claim concerned before giving the applicant an opportunity, upon entry into the national phase, to furnish the priority document within a time limit which is reasonable under the circumstances.

Priority date	Priority application No.	Country or regional Office or PCT receiving Office	Date of receipt of priority document
12 Nov 2002 (12.11.2002)	2002/328866	JP	09 Janu 2004 (09.01.2004)
22 Sept 2003 (22.09.2003)	2003/330775	JP	09 Janu 2004 (09.01.2004)

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No. (41-22) 338.70.10	Authorized officer Eric SANSON (Fax 338 7010) Telephone No. (41-22) 338 9999
--	--

Form PCT/IB/304 (January 2004)

008048316

COPY

PATENT COOPERATION TREATY

From the INTERNATIONAL BUREAU


PCT

**NOTICE INFORMING THE APPLICANT OF THE
COMMUNICATION OF THE INTERNATIONAL
APPLICATION TO THE DESIGNATED OFFICES**

(PCT Rule 47.1(e), first sentence)

To:

WATANABE, Mochitsahi
Hayakawa-tonakai Bldg. 3F
12-5, Iwamoto-cho 2-chome
Chiyoda-ku, Tokyo 101-0032
JAPON



Date of mailing (day/month/year)
27 May 2004 (27.05.2004)

Applicant's or agent's file reference
PCT222

IMPORTANT NOTICE

International application No.
PCT/JP2003/014389

International filing date (day/month/year)
12 November 2003 (12.11.2003)

Priority date (day/month/year)
12 November 2002 (12.11.2002)

Applicant

MOCHIDA PHARMACEUTICAL CO., LTD. et al

1. Notice is hereby given that the International Bureau has communicated, as provided in Article 20, the international application to the following designated Offices on the date indicated above as the date of mailing of this notice:

AU, AZ, BY, CH, CN, CO, DZ, EP, HU, JP, KG, KP, KR, MD, MK, MZ, RU, TM, US

In accordance with Rule 47.1(c), third sentence, those Offices will accept the present notice as conclusive evidence that the communication of the international application has duly taken place on the date of mailing indicated above and no copy of the international application is required to be furnished by the applicant to the designated Office(s).

2. The following designated Offices have waived the requirement for such a communication at this time:

AE, AG, AL, AM, AP, AT, BA, BB, BG, BR, BZ, CA, CR, CU, CZ, DE, DK, DM, EA, EC, EE, EG, ES, FI, GB, GD, GE,
GH, GM, HR, ID, IL, IN, IS, KE, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MG, MN, MW, MX, NI, NO, NZ, OA, OM, PG, PH,
PL, PT, RO, SC, SD, SE, SG, SK, SL, SY, TJ, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW

The communication will be made to those Offices only upon their request. Furthermore, those Offices do not require the applicant to furnish a copy of the international application (Rule 49.1(a-bis)).

3. Enclosed with this notice is a copy of the international application as published by the International Bureau on 27 May 2004 (27.05.2004) under No. WO 2004/044005

4. **TIME LIMITS** for filing a demand for international preliminary examination and for entry into the national phase

The applicable time limit for entering the national phase will, subject to what is said in the following paragraph, be 30 MONTHS from the priority date, not only in respect of any elected Office if a demand for international preliminary examination is filed before the expiration of 19 months from the priority date, but also in respect of any designated Office, in the absence of filing of such demand, where Article 22(1) as modified with effect from 1 April 2003 applies in respect of that designated Office. For further details, see *PCT Gazette* No. 44/2001 of 1 November 2001, pages 19926, 19932 and 19934, as well as the *PCT Newsletter*, October and November 2001 and February 2002 issues.

In practice, time limits other than the 30-month time limit will continue to apply, for various periods of time, in respect of certain designated or elected Offices. For regular updates on the applicable time limits (20, 21, 30 or 31 months, or other time limit), Office by Office, refer to the *PCT Gazette*, the *PCT Newsletter* and the *PCT Applicant's Guide*, Volume II, National Chapters, all available from WIPO's Internet site, at <http://www.wipo.int/pct/en/index.html>.

For filing a demand for international preliminary examination, see the *PCT Applicant's Guide*, Volume IA, Chapter IX. Only an applicant who is a national or resident of a PCT Contracting State which is bound by Chapter II has the right to file a demand for international preliminary examination (at present, all PCT Contracting States are bound by Chapter II).

It is the applicant's sole responsibility to monitor all these time limits.

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Authorized officer

Masashi Honda

Facsimile No. +41 22 740 14 35

Facsimile No. +41 22 338 70 10

Form PCT/IB/008 (April 2002)